Global Alzheimers Therapeutics Market Size & Outlook
Global alzheimers therapeutics market, 2018-2030 (US$M)
Related Markets
Global alzheimers therapeutics market highlights
- The global alzheimers therapeutics market generated a revenue of USD 4,207.8 million in 2022 and is expected to reach USD 16,157.9 million by 2030.
- The market is expected to grow at a CAGR (2023 - 2030) of 18.3% by 2030.
- In terms of segment, cholinesterase inhibitors accounted for a revenue of USD 2,187.9 million in 2022.
- Monoclonal Antibodies is the most lucrative drug class segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2022.
- Country-wise, UAE is expected to register the highest CAGR from 2023 to 2030.
Global data book summary
| Market revenue in 2022 | USD 4,207.8 million |
| Market revenue in 2030 | USD 16,157.9 million |
| Growth rate | 18.3% (CAGR from 2022 to 2030) |
| Largest segment | Cholinesterase inhibitors |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drugs, Monoclonal Antibodies |
Other key industry trends
- In terms of revenue, the North America accounted for 41.0% of the global alzheimers therapeutics market in 2022.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, UAE is the fastest growing regional market and is projected to reach USD 17.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Alzheimers Therapeutics Market Scope
Alzheimers Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global alzheimers therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alzheimers therapeutics market will help companies and investors design strategic landscapes.
Cholinesterase inhibitors was the largest segment with a revenue share of 52% in 2022. Horizon Databook has segmented the Global alzheimers therapeutics market based on cholinesterase inhibitors, nmda receptor antagonist, combination drugs, monoclonal antibodies covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Alzheimers Therapeutics Drug Class Outlook (Revenue, USD million, 2018-2030)
- Cholinesterase inhibitors
- NMDA Receptor Antagonist
- Combination Drugs
- Monoclonal Antibodies
- Other pipeline drugs
- Global Alzheimers Therapeutics End User Outlook (Revenue, USD million, 2018-2030)
- Hospital Pharmacy
- Retail Pharmacy
- E-commerce
Reasons to subscribe to Global alzheimers therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global alzheimers therapeutics market databook
-
Our clientele includes a mix of alzheimers therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global alzheimers therapeutics market , including forecasts for subscribers. This global databook contains high-level insights into Global alzheimers therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global alzheimers therapeutics market size, by regions, 2018-2030 (US$M)
Top 10 countries: Alzheimers therapeutics market size, 2022 (US$M)
Global alzheimers therapeutics market share, by drug class, 2022 & 2030 (%, US$M)
Alzheimers therapeutics market: Opportunity assessment by country
Global alzheimers therapeutics market, by region, 2022 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
